Depression has long been associated with reductions in key neurotransmitters (serotonin, norepinephrine and dopamine), but only recently have researchers come to understand what causes their depletion. New neuroimaging techniques have shown that these neurotransmitters are depleted due to the over- expression of monoamine oxidase A (MAO-A). TriRima is the first and only medication that specifically blocks MAO-A, thereby allowing neurotransmitter levels to normalize. This approach differs from traditional antidepressants, which seek to overcome low neurotransmitter levels primarily by concentrating the existing neurotransmitters in the gap between the neurons (the synaptic cleft), leaving the neurons themselves with a neurotransmitter deficit. By blocking MAO-A and allowing the neurotransmitters to return to normal levels, TriRima acts to correct the neurotransmitter deficit both within the neuron and within the synaptic cleft. TriRima's target is accordingly differentiated and upstream to the approach of most traditional classes of antidepressants, with the potential for improved efficacy.
TriRima is a selective and reversible member of a novel class of drugs known as RIMAs, or reversible inhibitors of monoamine oxidase A. TriRima acts to normalize the levels of three key neurotransmitters that positively affect mood and anxiety, and the selectivity and reversibility of TriRima are expected to eliminate or reduce the risk of food-associated cardiovascular effects of conventional MAO inhibitors.
Separately, CeNeRx announced that it has successfully filed an IND to assess CXB909 as a potential treatment for Alzheimer's disease. CXB909, w
|SOURCE CeNeRx BioPharma, Inc.|
Copyright©2010 PR Newswire.
All rights reserved